China's FDA has approved Roche's ($RHHBY) Avastin (bevacizumab) for an additional indication of non-small lung cancer, a pending decision that was tipped in the first quarter earnings call. "We can confirm that Avastin was approved by China Food and Drug Administration (CFDA) for the first-line treatment of advanced metastatic non-squamous NSCLC," Roche spokeswoman Nina Schwab said in an email to FiercePharmaAsia. In April, Daniel O'Day, the company's chief operating officer, said on the first quarter earnings call that the company expected the new indication approval in the second half of this year for non-small cell lung cancer. Lung cancer is the most prevalent of cancers in China. Roche filed the additional indication application in June 2014, with treatment outside of China normally in combination with carboplatin and paclitaxel for patients that have not received chemotherapy. Avastin is already approved for colorectal cancer in China, with competition from Merck Serono's Erbitux (cetuximab).